Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The mechanistic target of rapamycin (mTOR) is a kinase forming two complexes: mTORC1 and mTORC2.
• mTORC1 regulates protein synthesis and cell growth, influenced by nutrients, growth factors, and neurotransmitters.
• mTORC2 is modulated by growth factors and affects cell signaling pathways.

Purpose of the Study:

• To review the regulation of mTOR signaling.
• To discuss the therapeutic targeting of mTOR complexes in cancer treatment.
• To explore the role of mTOR in cancer stem cells, including glioblastoma.

Main Methods:

• Literature review of mTOR regulation and function.
• Analysis of mTOR complex inhibition strategies.
• Examination of mTOR's role in tumorigenesis and cancer stem cells.

Main Results:

• Aberrant mTOR activation contributes to cancer development.
• Rapamycin and rapalogues partially inhibit mTORC1 via allosteric mechanisms.
• ATP-catalytic inhibitors target both mTORC1 and mTORC2.

Conclusions:

• mTOR pathway dysregulation is a key factor in various cancers.
• Targeting mTOR complexes offers a promising therapeutic strategy for cancers, including glioblastoma.
• Inhibiting mTOR may be effective against cancer stem cells.